---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036262"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-08-06T12:00:18+00:00"
generated_at: "2026-08-06T12:06:14.130926+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MIRA reports positive 7-day dog study for obesity drug SKNY-1; de-risks dose selection

## Summary
- SKNY-1 showed rapid oral absorption and dose-dependent systemic exposure in Beagle dogs over 7 days.
- Plasma concentrations were comparable between male and female animals.
- Data demonstrates dose-dependent response and systemic accumulation with repeated dosing.
- Findings de-risk dose selection and support advancement toward GLP toxicology and IND-enabling studies.
- SKNY-1 aims to preserve lean body mass while promoting weight reduction in obesity.

## SEC filing metadata
- accession: 0001493152-26-036262
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-08-06T12:00:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226036262/0001493152-26-036262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226036262/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036262
- JSON: https://secwatch.observer/filing/0001493152-26-036262.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036262.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.